Review article: Antibiotic-induced Clostridium difficile infection

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 835-841

  Settle, C D ^a   Wilcox, M H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; METRONIDAZOLE; VANCOMYCIN;

BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; DRUG COST; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0029823366     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.79251000.x     Document Type: Review

References (64)

1. Larson HE, Price AB, Honour P. Borriello SP. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978; i: 1063-6.
2. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med 1978; 298: 531-4.
3. Department of Health and Public Health Laboratory Service Joint Working Group. Clostridium difficile infection. Prevention and management. Department of Health and Public Health Laboratory Service, London, 1994.
4. Cartmill TDI, Panigrahi H, Worsley MA, et al. Management and control of a large outbreak of diarrhoea due to Clostridium difficile. J Hosp Infect 1994; 27: 1-15.
5. Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired Clostridum difficile infection. J Hosp Infect 1996; 34: 23-30.
6. Borriello SP, Barclay FE. Colonisation resistance to Clostridium difficile infection. Microecol Ther 1984; 14: 75-87.
7. Kamthan AG, Brukner HW, Hirschman SZ, Agus SG. Clostridium difficile diarrhea induced by cancer chemotherapy. Arch Intern Med 1992; 152: 1715-7.
8. Committee on Safety of Medicines. Antibiotic associated colitis. Curr Probl Pharmacovigilance 1994; 20: 7-8.
9. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile diarrhoea. Am J Gastroenterol 1994; 89: 519-23.
10. Ambrose NS, Johnson M, Burdon DW, Keighley MRB. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother 1985; 15: 319-26.
11. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991; 35: 208-10.
12. de Lalla F, Privitera G, Ortisi G, et al. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. J Antimicrob Chemother 1989: 23: 623-31.
13. Borriello SP. Pathogenesis of Clostridium difficile infection of the gut. J Med Microbiol 1990; 33: 207-15.
14. Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983; 148: 93-100.
15. Rudcnsky B, Rosner S, Sonnenblick M, et al. The prevalence and nosocomial acquisition of Clostridium difficile in elderly hospitalized patients. Postgrad Med J 1993; 69: 45-7.
16. Bender BS, Laughton BE, Gaydos C, et al. Is Clostridium difficile endemic in chronic care facilities? Lancet 1986; ii: 11-3.
17. George WL, Sutter VL, Finegold SM. Toxigenicity and antimicrobial susceptibility of Clostridium difficile, a cause of antimicrobial agent-associated colitis. Curr Microbiol 1978; 1: 55-8.
18. Mardh PA, Helen I, Colleen I, Öberg M, Holst E. Clostridium difficile toxin in faecal specimens of healthy children and children with diarrhoea. Acta Paediatr Scand 1982; 71: 275-8.
19. Mitchell TJ, Ketley JM, Haslam SC, et al. The effect of toxins A and B of Clostridium difficile on rabbit ileum and colon. Gut 1986; 27: 78-85.
20. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1988; 1: 1-18.
21. Borriello SP, Ketley JM, Mitchell TJ, et al. Clostridium difficile - a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. J Med Microbiol 1987; 24: 53-64.
22. Borriello SP, Welch AR, Barclay FE, Davies HA. Mucosal association by Clostridium difficile in the hamster gastrointestinal tract. J Med Microbiol 1988; 25: 191-6.
23. Seddon SV, Hemingway I, Borriello SP. Hydrolytic enzyme production by Clostridium difficile and its relationship to toxin production and virulence in the hamster model. J Med Microbiol 1990; 31: 169-74.
24. Dailey DC, Kaiser A, Schloemer RH. Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leucocytes. Infect Immun 1987; 55: 1541-6.
25. Fekety R. Antibiotic-associated colitis. In : Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 4th edn. Edinburgh: Churchill Livingstone, 1994: 978-87.
26. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6 (Suppl. 1): S235-41.
27. Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic associated colitis with vancomycin. J Antimicrob Chemother 1984; 14 (Suppl. D): 97-102.
28. George WL, Sutter VL, Citron D, Finegold SM. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979; 9: 214-9.
29. Borriello SP, Honour P. Simplified procedure for the routine isolation of Clostridium difficile from faeces. J Clin Pathol 1981; 34: 1124-7.
30. Willey SH, Bartlett JG. Culture for Clostridium difficile in stools containing a cytotoxin neutralised by Clostridium sordellii antitoxin. J Clin Microbiol 1979; 10: 880-4.
31. Bond F, Payne G, Borriello SP, Humphreys H. Usefulness of culture in the diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 1995; 14: 223-6.
32. Bowman RA, Riley TV. Isolation of Clostridium difficile from stored specimens and comparative susceptibility of various tissue culture cell lines to cytotoxin FEMS Microbiol Lett 1986; 34: 31-5.
33. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med 1978; 298: 531-4.
34. George WL, Rolfe RD, Finegold SM. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial associated diarrhea and miscellaneous conditions. J Clin Micrbiol 1982; 15: 1049-53.
35. Bartlett JG. Antibiotic-associated colitis. Clin Gastroenterol 1979; 8: 783.
36. Brazier JS. The laboratory diagnosis of Clostridium difficile-associated disease. Rev Med Micobiol 1995; 6: 236-45.
37. Borriello SP, Wren BW, Hyde S. et al. Molecular, immunological and biological characterisation of a toxin A-negative. toxin B-positive strain of Clostridium difficile. Infect Immun 1992; 60: 4192-9.
38. Depitre C, Delmee M, Avesani V, et al. Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol 1993; 38: 434-41.
39. Lyerly DM, Wilkins TD. Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol 1986; 23: 622-3.
40. West S, Wilkins TD. Problems associated with counter-immunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol 1982; 15: 347-9.
41. Levett PN. Detection of Clostridium difficile in faeces by direct gas-liquid chromatography. J Clin Path 1984: 37: 117-9.
42. Olson MM, Shanholtzer J, Lee JT, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994; 15: 371-81.
43. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; ii: 1043-6.
44. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect 1992; 22: 85-92.
45. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic associated colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 15-9.
46. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36: 673-9.
47. Burdon DW. Treatment of pseudomembranous colitis and antibiotic-associated diarrhoea. J Antimicrob Chemother 1984; 14 (Suppl. D): 103-9.
48. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clin Infect Dis 1993; 16: 750-5.
49. Novak E, Lee JG, Seckman CE, Phillips JP, Disanto AR. Unfavourable effect of atropine-diphenoxylate (Lomotil) therapy in lincosamide caused diarrhea. J Am Med Assoc 1976; 235: 1451-4.
50. Wallery T, Milson D. Loperamide-related toxic megacolon on Clostridium difficile colitis. Postgrad Med J 1990; 66: 582.
51. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989; 159: 340-3.
52. O'Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 1991; 107: 627-35.
53. McFarland LV, Bernasconi P. Saccharornyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 1993; 6: 157-71.
54. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; ii: 1519.
55. McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis 1996; 22: 200-1.
56. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic associated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867-8.
57. Buggy BP. Clostridium difficile colitis: causes, cures. J Am Med Assoc 1993; 269: 2088.
58. Leving DYM, Kelly CP, Boguniewicz M. et al. Treatment with intravenously administered gamma globulin of relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118: 633-7.
59. Mulligan ME, Rolfe RD, Finegold SM, George WL. Contamination of a hospital environment by Clostridium difficile. Curr Microbiol 1979; 3: 173-5.
60. Fekerty R, Kim KH, Batts DH, Cudmore M, Silva J Jr. Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med 1981; 70: 906-8.
61. Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD. Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996; 100: 32-40.
62. Bettin K, Clabots C, Mathie P, Willard K, Gerding DN. Effectiveness of liquid soap vs. chlorhexidene gluconate for the removal of Clostridium difficile from bare hands. Infect Control Hosp Epidemiol 1994; 15: 697-702.
63. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-10.
64. Johnson S, Homann SR, Bettin KM. et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 1992; 117: 297-302.